‘Bad News’: Adjuvant Denosumab Disappoints in Early Breast Cancer

Adjuvant denosumab failed to show any clinical benefit on bone metastasis or disease recurrence in high-risk, early breast cancer in the phase 3 D-CARE trial.

Read the full article here

Related Articles